Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

N-Power Medicine and New York Cancer & Blood Specialists partner to reduce size of oncology clinical trials and accelerate new therapies

N-Power Medicine and New York Cancer & Blood Specialists announced a strategic partnership to accelerate the generation of N-Power’s Prospective External Control Arms. This approach is designed to reduce the size of oncology clinical trials and bring new therapies to patients years sooner.

October 16, 2026

Vol.52 No.38

Perspective

Oncology has a semantics problem: How do we define “early stage”?

I recently found myself asking a question that I thought had an obvious answer: What is early-stage cancer?

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

NIH has introduced Linked Discoveries, an experimental tool designed to help scientists more easily see how an individual research finding relates to the larger body of biomedical evidence.

October 02, 2026

Vol.52 No.36

In Brief

ARPA-H launches SURPASS program to accelerate clinical trials

ARPA-H launched the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program, together with three complementary projects, aimed at removing barriers that slow clinical development and help promising treatments reach patients sooner.

October 02, 2026

Vol.52 No.36

Clinical Roundup

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial.

September 25, 2026

Vol.52 No.35

Clinical Roundup

PDS0101 + pembrolizumab in HPV16+ R/M head and neck cancer show anti-tumor activity, VERSATILE-002 phase II study finds

PDS0101 plus pembrolizumab showed antitumor activity in ICI-naive HPV16-positive R/M HNSCC, according to the results of a phase II trial.

September 25, 2026

Vol.52 No.35

Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

YOU MAY BE INTERESTED IN

N-Power Medicine and New York Cancer & Blood Specialists partner to reduce size of oncology clinical trials and accelerate new therapies

Oncology has a semantics problem: How do we define “early stage”?

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

ARPA-H launches SURPASS program to accelerate clinical trials

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

PDS0101 + pembrolizumab in HPV16+ R/M head and neck cancer show anti-tumor activity, VERSATILE-002 phase II study finds

Renew today!

Subscriber content

Never miss an issue!

Login